Related Experiment Video

Updated: Feb 9, 2026

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.6K

[Progress in the study of new cancer target Cdk5 and its inhibitors]

Long-xing Miao, Yi-jun Yang, Ze-yu Wang

    Yao Xue Xue Bao = Acta Pharmaceutica Sinica
    |June 2, 2018
    PubMed

    Insights

    Cyclin-dependent kinase-5 (Cdk5) hyperactivation drives tumor progression. Inhibitors targeting Cdk5, particularly its ATP-binding pocket and protein interfaces, show promise for cancer drug development.

    Area of Science:

    • Biochemistry
    • Molecular Biology
    • Oncology

    Background:

    • Cyclin-dependent kinase-5 (Cdk5) is a serine/threonine kinase crucial for neural development.
    • Aberrant Cdk5 activity is implicated in tumor evolution, progression, and apoptosis.
    • Cdk5 inhibitors are actively researched as anti-cancer therapeutics.

    Purpose of the Study:

    • To review the structural features and molecular mechanisms of Cdk5 inhibitors.
    • To highlight strategies for developing novel Cdk5-targeted cancer drugs.
    • To explore the potential of targeting Cdk5's ATP-binding pocket and protein-protein interfaces.

    Main Methods:

    • Literature review of Cdk5 inhibitor studies.
    • Analysis of structure-activity relationships for Cdk5 inhibitors.
    • Examination of drug design strategies targeting Cdk5.

    Main Results:

    • Cdk5 hyperactivation is linked to various cancers.
    • Inhibitors targeting the conserved ATP-binding pocket are a major focus in Cdk5 drug design.
    • Peptide-based inhibitors targeting protein-protein interfaces are emerging.

    Conclusions:

    • Cdk5 inhibitors represent a promising avenue for cancer therapy.
    • Understanding Cdk5 inhibitor structures and mechanisms aids drug development.
    • Targeting both the ATP-binding pocket and protein interfaces offers diverse therapeutic strategies.

    More Related Videos

    3D Cell-Printed Hypoxic Cancer-on-a-Chip for Recapitulating Pathologic Progression of Solid Cancer10:51

    3D Cell-Printed Hypoxic Cancer-on-a-Chip for Recapitulating Pathologic Progression of Solid Cancer

    Published on: January 5, 2021

    5.2K
    Bioluminescent Orthotopic Model of Pancreatic Cancer Progression09:25

    Bioluminescent Orthotopic Model of Pancreatic Cancer Progression

    Published on: June 28, 2013

    27.6K

    Related Concept Videos

    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
    The mTOR pathway or the...
    4.9K
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    9.0K
    Eukaryotic Transcription Inhibitors01:52

    Eukaryotic Transcription Inhibitors

    Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
    Eukaryotic transcription inhibitors usually contain two distinct domains, a...
    11.0K
    Mouse Models of Cancer Study02:43

    Mouse Models of Cancer Study

    Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
    The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
    6.6K
    Tumor Progression02:07

    Tumor Progression

    Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
    Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
    7.5K
    Dipeptidyl Peptidase 4 Inhibitors01:23

    Dipeptidyl Peptidase 4 Inhibitors

    Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
    687